▲ 0.13%
prev close
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-11-21 | GHGuardant Health, Inc. | Buy | $1,001 - $15,000 | 234d ago | — |
2025-11-21
Sheldon Whitehouse
GH
Amount
$1,001 - $15,000
Filed
234d ago
Recent News
Powered by Polygon.io
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider
Why Grail Could Be the Sleeper Stock Everyone's About to Notice
AI-Powered Imaging Systems and Deep Learning Software Revolutionize Cancer Diagnostics Market Globally
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Trade Timeline
Congressional activity, newest first
Sheldon Whitehouse
2025-11-21 · Purchase
$1,001 - $15,000